Results 31 to 40 of about 55,966 (208)

A novel interleukin 36 gamma for diagnosing and differentiating malignant from infectious pleural effusion

open access: yesEgyptian Journal of Chest Disease and Tuberculosis
Background Pleural effusions can be caused by various diseases, making their diagnosis challenging. Light’s criteria are often used to distinguish transudative and exudative effusions.
Nashwa A. Amin   +6 more
doaj   +1 more source

Diagnostic value of procalcitonin in pleural effusion

open access: yesEgyptian Journal of Chest Disease and Tuberculosis, 2020
Background A wide range of diseases can cause pleural effusion. Its diagnosis and management remain a clinical challenge, bearing a significant cost to both patients and health care system.
Abdelsadek H Al-Aarag   +3 more
doaj   +1 more source

Managing malignant pleural effusion

open access: yesCleveland Clinic Journal of Medicine, 2019
Malignant pleural effusion can be managed in different ways, including clinical observation, thoracentesis, placement of an indwelling pleural catheter, and chemical pleurodesis. The optimal strategy depends on a variety of clinical factors. This article uses cases to illustrate the rationale for determining the best approach in different situations.
Ali Saeed, Wahla   +3 more
openaire   +2 more sources

Posthumously Diagnosed Myhre Syndrome Presenting With Pleural Remodeling and Endometrial Cancer

open access: yesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT Myhre syndrome (OMIM 139210) is a genetic condition defined by neurodevelopmental disability, characteristic facial features, and multisystem proliferative fibrosis. While various types of lung disease have been reported, pleural remodeling leading to restrictive lung disease has not yet been described.
Jeanette Saffir   +6 more
wiley   +1 more source

Diagnostic value of calprotectin in differentiation between benign and malignant pleural effusion

open access: yesThe Egyptian Journal of Bronchology, 2019
Background Pleural effusion can arise as a result of more than 50 recognized causes and the differentiation between benign and malignant origin of the fluid is still a diagnostic challenge.
Omar M. Mohammed   +5 more
doaj   +1 more source

Treatment of malignant pleural effusion

open access: yesJournal of Visualized Surgery, 2018
Malignant pleural effusion (MPE) is a very disabling condition that often affects patients with advanced neoplasm. Conservative approach, repeated thoracentesis, pleurodesis and use of indwelling pleural catheters (IPC) are the main methods to deal with this condition.
Ricardo Mingarini, Terra   +1 more
openaire   +3 more sources

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Cytological Features of Clear Cell Sarcoma in Exfoliative and Effusion Cytology Specimen—A Case Report and Literature Review

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Clear cell sarcoma of soft tissue (CCSST) with malignant effusion is a rare yet clinically aggressive appearance, which may pose a diagnostic pitfall with its overlapping cytomorphologic features with metastatic melanoma and carcinoma.
William H. Wu   +2 more
wiley   +1 more source

Diagnostic significance of pleural fluid pH and pCO2

open access: yesEgyptian Journal of Chest Disease and Tuberculosis, 2015
The diagnosis of pleural effusion is still difficult. The presence of pleural effusion can be confirmed by radiological studies including simple chest radiography, ultrasonography, or computed tomography.
K.E. Sobhey, B.A. Naglaa
doaj   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

open access: yesInternational Journal of Cancer, EarlyView.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy